Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin plus cetuximab in KRAS-mutant metastatic colorectal cancer
2009-017384-42Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and simvastatin in colorectal cancer (CRC), sponsored by Leiden University Medical Center. Primary endpoint: Progression-free and alive at 12.5 weeks after first cetuximab dose. Started Feb 2010; status: active.
02
Drugs
cetuximabsimvastatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2009-017384-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017384-42.